Stocks making the biggest moves midday: Manpower, Abbott, UnitedHealth, TSMC & more

Big midday movers were driven by earnings beats, guidance raises, and one major deal: Abbott jumped ~11% after raising full-year adjusted EPS guidance to $5.45–$5.60 vs prior $5.38–$5.58 (FactSet $5.47). ManpowerGroup surged ~33% on stronger Q2 adjusted EPS (99c vs 95c) and raised revenue growth expectations (Q3 +2% to $6% vs 1.7% consensus), while UnitedHealth rose ~4% after Q2 results beat and full-year outlook was hiked. In contrast, AST SpaceMobile fell >16% after announcing $1B of convertible notes, and AtaiBeckley rallied ~33% as Eli Lilly agreed to buy it for $2.8B cash ($6.75/share, +26%).

Analysis

The clearest signal is not the beats themselves, but the market rewarding businesses with visible pricing power and penalizing capital-intensive “story” names. That argues for continued relative strength in high-quality defensive compounders like UNH, ABT and CTAS, while anything dependent on external financing or a future utilization ramp stays vulnerable to multiple compression. In the next 1-3 months, the key differentiator will be whether these companies convert earnings beats into sustained guidance lift and margin durability rather than one-quarter noise.

Transport is splitting into winners and losers: JBHT’s intermodal strength suggests freight is stabilizing, but UAL’s fuel-cost squeeze shows airlines are still one macro shock away from margin resets. That makes a cleaner relative trade in transport than a directional bet on the group; the setup favors assets with low fuel sensitivity and operating leverage from volume recovery over airlines that are exposed to both demand and energy.

TSM’s higher capex is a subtle negative for near-term free cash flow and ROIC optics, even if it reinforces the long-cycle AI thesis. The second-order winners are the upstream semiconductor toolchain, not necessarily TSM stock itself; if AI demand does not accelerate further, the market could begin to question whether capex is outpacing monetization. ASTS is the opposite: the financing removes a near-term liquidity overhang but also introduces dilution risk, so the stock can stay under pressure until the deal terms prove benign and execution milestones are visible. The contrarian miss is that the market is treating several of these as “earnings beats,” when the real issue is whether the new guidance is sustainable enough to justify the next leg of multiple expansion.

Key Decisions for Investors

• Long UNH on any post-print fade over the next 1-3 weeks; target a continuation move over 1-3 months, but exit if next utilization or medical-cost commentary deteriorates enough to threaten the raised full-year view.
• Buy ASTS put spreads or short ASTS common into the financing overhang for a 2-8 week trade; cover if the convert is priced with limited dilution or if management secures strategic capital on better terms than expected.
• Pair trade: long JBHT / short UAL for 1-2 months to express the gap between intermodal recovery and airline fuel-cost pressure; thesis fails if crude retraces sharply or UAL resets guidance upward.
• Add to CTAS only on pullbacks, not on the gap, for a 6-12 month compounder setup; the trade is invalidated if margin expansion stalls or labor-vertical growth slows materially.